Bicycle therapeutics selected to participate in fda program to expedite commercial manufacturing readiness of bt8009 for metastatic bladder cancer

Cambridge, england & boston--(business wire)--bicycle therapeutics (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that bt8009, the company's lead investigational therapy in development to treat metastatic bladder (urothelial) cancer, has been selected to participate in the chemistry, manufacturing and controls (cmc) development and readiness pilot (cdrp) program re.
BCYC Ratings Summary
BCYC Quant Ranking